Stone, SP:Carabao rash. (letter) Arch Derm., 102:564, 1979.
Stone, SP, Muller, SA, and Gleich, GJ:IgE Levels in atopic dermatitis. Arch Derm., 108:806, 1973.
Stone SP. Bullous pemphigoid (letter) Arch Dermatol. 1974 Nov;110(5):812
Stone SP. Delayed blanch in alopecia mucinosa. (letter) Arch Dermatol. 1975 Jan;111(1):132.
Stone, SP, and Schroeter, AL:Bullous pemphigoid and associated malignant neoplasms. Arch Derm., 111:994, 1975.
Stone, SP:Urticaria, Journal of Family Practice, 2:6, 455, December 1975.
Stone, SP:Cutaneous clues to cancer, American Family Physician, 12:4, 83, October 1975.
Stone, SP, Gleich, GJ, and Muller, SA:Atopic dermatitis and IgE: relationship between changes in IgE levels and severity of disease.Arch Derm., 112:1254, 1976.
Stone, SP:Scabies.American Family Physician, 14:152, May 1977.
Stone, SP, and Goodwin, RM:Dapsone induced jaundice, Arch Derm., 114:6, 47, June 1978.
Stone, SP:Electrodessication and fulguration of lesions of the skin, Journal of Family Practice, 8:1, 171 - 174, January 1979.
Stone, SP:Basal cell nevus syndrome and adenocarcinoma of the colon: response to intravenous 5-fluorouracil. International Journal of Dermatology, 18:5, 398 - 401. June 1979.
Stone, SP:"Rosacea" in Conn, H:Current Therapy: 1979, W. B. Saunders (Philadelphia) 1979.
Stone, SP:Long Term Effects of Tetracycline (amenorrhea).Journal of the American Academy of Dermatology (correspondence), 1:2, 151, August 1979.
Stone SP, Goodwin RM, Evans DJ.Survival of Sarcoptes scabiei. J Am Acad Dermatol. 1980 Aug;3(2):208-9.
Stone, SP:"Management of the Itchy, Scaly Scalp" in Current Concepts in Skin Disorders, 2:2, 9 - 11, Summer 1981.
Wortsman J., Dietrich J., Traycoff R. B., Stone S. P.:Preradial Myxedema in Thyroid Disease.Arch Derm., 117,10: 635-638, October 1981.
Stone SP. Topical application of bichloroacetic acid J Dermatol Surg Oncol 1992Mar;18(3):253(Letter – Comment)
Stone, SP:"Pruritus Ani and Vulvae" in Conn, H:Conn's Current Therapy 1994,W. B. Saunders (Philadelphia).
Stone, SP: “Unusual, Innovative, and Long-Forgotten Remedies” in Dermatological Clinics, Theirs,BH: ed. 18:2. 323-338, April 2000.
Malafa, MP, McKesey, P., Stone, SP et al: Sentinel Node Biopsy for Staging ofAggressive Digital Papillary Adenocarcinoma. Dermatologic Surgery, 6:6 580-583, June 2000.
Stone SP: Babies, Bath Water, and Accutane, Clinics in Dermatology,19:1 91-92, Jan-Feb, 2001.
Stein S, Stone SP, Paller AS:Ongoing Blistering in a Boy with Congenital Erosive and Vesicular Dermatosis Healing with Reticulated Supple Scarring, J Am Acad Dermatol; 45:6 (Pt 1): 946-8 Dec2001.
Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA: Validity and reliability of patient reported outcomes used in Psoriasis: results from two randomized clinical trialsHealth and Quality of Life Outcomes 2003, 1:53 (08 Oct 2003).
Stone SP, Langley R (eds.): Biologic Bulletin, Recent Developments in Targeted T-Cell Therapy for Psoriasis, CD-ROM, Dannemiller Memorial Educational Foundation and Helix Medical Communications, Dec 2003.
Papp KA, Camisa C, Stone SP, Caro I, Wang X, Compton P, Walicke PA, Gottlieb AB. Safety of Efalizumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: Review of Clinical Data: Part II. J Cutan Med Surg. 2006 May 25; [Epub ahead of print]
Stone SP, Buescher LS: Life-threatening Paraneoplastic Cutaneous Syndromes Clin Dermatol.;23(3):301-6. May-Jun 2005.
Lim HW, Gilchrest BA, Cooper KD, Bischoff-Ferrari HA, Rigel DS, Cyr WH, Miller S, DeLeo VA, Lee TK, Demko CA, Weinstock MA, Young A, Edwards LS, Johnson TM, Stone SP: Sunlight, tanning booths, and vitamin D. J Am Acad Dermatol. 52(5):868-76. May; 2005.
DeWitt CA Bishop AB, Buescher LS, Stone SP:Hyperimmunoglobulin E syndrome: two cases and a review of the literature.Journal of the American Academy of Dermatology; 54(5):855-65, May 2006.
CA, Neely MJ, Stone SP, Goldfarb JN: Painful plaques and cicatricial alopecia in a young woman. Archives of Dermatology submitted
CA, Siroy AE, Semans B, Stone SP: Acneiform eruptions induced by epidermal growth factor receptor targeted chemotherapy. J Am Acad Dermatol. 2006 Dec 11; [Epub ahead of print] 56(3):500-5 2007 Mar.
Wolf R, Davidovici B, Stone SP Tuzun Y: In pursuit of defining clinical relevance of positive patch tests results. Clin Dermatol. 2007 Sep-Oct;25(5):493-4.
Reid E, Baker B, Stees M, Stone SP: Buschke-Ollendorff syndrome: A 32-month old boy with elastomas and craniosynostosis. Pediatric Dermatology, 25(3):349-351, May/June 2008.
Wolf R, Wolf D, Stone SP, Davidovici B: Challenging the classification of clinical relevance of positive patch tests results in allergic contact dermatitis: a report on an infant. Int J Dermatol. 2008 Nov;47(11):1193-4.
BOOK CHAPTERS
Stone SP: “Scabies and pediculosis” in Norman, RA, ed. Geriatric Dermatology, Parthenon Publishing Group, 2001.
Stone SP: “Scabies and pediculosis” Fitzpatrick's Dermatology in General Medicine 6th ed. 2004.
CA, Buescher LS, Stone SP “Chapter 154: Cutaneous Manifestations of Internal Malignant Disease: Cutaneous Paraneoplastic Syndromes” Fitzpatrick's Dermatology in General Medicine 7h ed. 2007.
Stone SP, Goldfarb JN, Bacelieri RE“Chapter 208: Scabies, Pediculosis and other Mites” Fitzpatrick's Dermatology in General Medicine 7h ed. 2007
REVIEWER
Archives of Dermatology
Journal of the American Academy of Dermatology
Pediatric Dermatology
Journal of Burns
Clinical and Experimental Dermatology
EDITORIAL
Dialogues in Dermatology
- Associate Editor 1976 - 1983
- Editor-in-Chief 1983 – 2001
- Consulting Editor 2001 – 2003
- Immediate Past Editor 2001-- 2009
Clinics in Dermatology
- Editorial Board 2000 –
- Comment and Controversy Section Editor 2001
Derm Coding Consult (American Academy of Dermatology)
- Editorial Advisory Board 2002 - 2006
National Psoriasis Foundation
- Editorial Review Committee 2003
Cutis
PHARMACEUTICAL STUDIES:
1987 CLP-503 A comparison of Temovate (clobetisol propionate) cream 0.5% and Topicort (desoximetasone) cream 0.25% in the treatment of hand and foot eczema.
1988 FLT-335 A Multi-Center Double-Blind Active and Placebo Controlled Parallel Study of the Efficacy and Safety of .005% and .05% Fluticasone Propionate Cream in the treatment of Moderate to Severe Psoriasis (87-100).
1997 AI459-011 A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Lobucavir in Patients with Recurrent Genital Herpes.
1997 AI459-012 A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Oral Lobucavir in Patients with Recurrent Herpes Labialis.
1998 PDC501-006 A Multi-Center Double-Blind Study to Evaluate the Safety and Efficacy of Butenafine HCL/Betamethasone Dipropionate Cream in the Treatment of Tinea Pedis.
1999 HS2A/B30009 A Randomized, Double Blind, Placebo Controlled Evaluation of Valacyclovir for the Prevention of Herpes Simplex Virus Transmission in Heterosexual Couples.
2000 ACD2059g A Phase III, Randomized, Double Blind, Placebo Controlled Multicenter, Multidose Study to Evaluate the Efficacy and Safety of Subcutaneously Administered Anti-CD11a in Adults with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy
2001 1393IMIQ A Vehicle Controlled, Double Blind Study To Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinoma
2002 1423-RESI A Phase III, Vehicle Controlled Study of Topical Resiquimod (R-848) 0.01% Gel Applied 2 Times per Week for 2 Weeks for Each Recurrence of Anogenital Herpes over 12 Months (Study suspended/terminated early)
2002 016.0039 A Multicenter Dose Ranging Study of the Safety and Efficacy of Enbrel in Psoriasis
2002 ACD2600 A Phase IIIb, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety of 1.0mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis
2002 BMV.C.302 A Multicenter, Randomized, Double Blind, Vehicle Controlled Study of the Safety and Efficacy of Luxiq® (betamethasone valerate) Foam, 0.12% in the Treatment of Moderate to Severe Atopic Dermatitis (Study on hold)
2002 49653/331 A Randomized, Double Blind, Placebo controlled, Parallel-Group Study to Assess the Safety and Efficacy of Rosiglitazone Maleate versus Placebo in the Treatment and Maintenance of Effect in Chronic Plaque Psoriasis (co-investigator)
2003 ACD2601g An Open-Label, Multicenter Study to Evaluate the Safety of1.0mg/kg Subcutaneously Administered Efalizumab in Adults with Moderate to Severe Plaque Psoriasis Who Previously Enrolled in Study ACD2600g.
2003 20030115 An Open-Label, Long-Term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adults
2004 20030190 A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis.
2004 190168-066P A Multi-Center, Investigator-Masked Randomized Safety and Efficacy Study of 12-Weeks Treatment with Tazarotene 4.5mg Capsules Administered Orally Once Daily vs. Efalizumab 1mg/kg Administered Subcutaneously Once Weekly vs. Tazarotene 4.5mg Capsules Administered Orally Once Daily Plus Efalizumab 1mg/kg Administered Subcutaneously Once Weekly Followed by a 12-Week Post-Treatment Follow-Up Period in Patients with Moderate to Severe Plaque Psoriasis.
2004 BAP0008 Efficacy and Safety of BAL4079 in the Treatment of Severe Chronic Hand Dermatitis Refractory to Topical Therapy. (Study terminated before opening).
2004 5326-04 A Phase 2 Study of STA-5326 As Monotherapy In Patients with Chronic Moderate to Severe Plaque Psoriasis.
2004 M03-656 A Phase 3, Multicenter Study of the Efficacy and Safety of Long-term Adalimumab Treatment in Subjects with Moderate to Severe Chronic Plaque Psoriasis.
2004 HS2100275 An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valaciclovir 1g Once Daily vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Infected Immunocompetent Subjects. (GlaxoSmithKline)
2004-2005 An Open-label, Long-term Extension Study to Assess the Safety of Etanercept in the Treatment of Psoriasis in Adult Subjects. (Amgen)
2004 20030190 A Multicenter, Open-Label, Prospective Study to Evaluate the Effectiveness and Safety of Etanercept in the Treatment of Subjects with Psoriasis. (Amgen)
2004 190168-066P Allergan study titled: “A Multicenter, Investigator-Masked, Randomized Safety and Efficacy Study of 12 Weeks Treatment with Tazarotene 4.5 mg Capsules Administered Orally Once Daily vs. Efalizumab 1 mg/kg Administered Subcutaneously Once Weekly vs. Tazarotene 4.5 mg Administered Once Daily Plus Efalizumab 1 mg/kg Administered Subcutaneously Once Weekly followed by a 12 Week Post Treatment Follow up Period in Patients with Moderate to Severe Plaque Psoriasis”.
2004 BAP00088 Basilea study titled: “Efficacy and Safety of BAL4079 in the Treatment of Severe Chronic Hand Dermatitis Refractory to Topical Therapy”.
2004 CSF0327C-2301 Novartis study titled: “A Randomized, Investigator Blinded, Active-Controlled, Parallel-Group Study to Compare the Efficacy and Safety of 6-week Treatment with Terbinafine New Pediatric Formulation Versus 6-week Treatment with Griseofulvin Pediatric Suspension in Children with Tinea Capitis”.
2004-2005 GlaxoSmithKline study titled: “A Randomized, Double-Blind, Placebo-Controlled, Multicenter 60-Day Study Comparing the Efficacy of Valtrex 1 Gram Once Daily vs. Placebo Once Daily in Reducing Viral Shedding in Immunocompetent Subjects with Recurrent Genital Herpes”.
2005 MO3-656 Abbott study titled: “A Phase 3, Multicenter Study of the Efficacy and Safety of Long-Term Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis.”
2005 ACD3101g Genentech study titled: “Raptiva® Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE) in Patients with Chronic Moderate to Severe Plaque Psoriasis”.
2005 CPE.C.301 Connetics study titled: “A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of Ethanol-Free Clobetasol Propionate Foam, 0.05% in the Treatment of Moderate to Severe Atopic Dermatitis.”
2006 Amgen study titled: “Observational Post-Marketing Safety Surveillance Registry of Enbrel® for the Treatment of Psoriasis” Protocol 20040210.
2006 Fujisawa study titled: “APPLES: A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis” Protocol FHI 03-0-161/FG-506-06-37.
2006 Novartis study titled: “A 52-Week Open-Label Intermittent Treatment to Evaluate the Long-Term Safety of pimecrolimus cream 1% in seborrheic dermatitis” Protocol CASM981N2301.
